menu search

CTMX / Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?

Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
CytomX Therapeutics (NASDAQ: CTMX ) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN ). This strategic partnership will see the two companies working together on the development of cancer therapies. Read More
Posted: Nov 17 2022, 10:47
Author Name: InvestorPlace
Views: 110722

CTMX News  

CytomX Therapeutics to Present at Upcoming September Investor Conferences

By GlobeNewsWire
September 5, 2023

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activ more_horizontal

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
August 25, 2023

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this tec more_horizontal

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice Pres more_horizontal

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 8, 2023

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to more_horizontal

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
June 1, 2023

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activa more_horizontal

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 9, 2023

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Acco more_horizontal

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 9, 2023

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to more_horizontal

CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 27, 2023

CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance more_horizontal


Search within

Pages Search Results: